Do analysts prefer PBM or CASI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PBM or CASI more profitable?

Psyence Biomedical has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A CASI Pharmaceuticals -183.93% N/A -131.54%

Do analysts recommend CASI or CNSP?

CNS Pharmaceuticals has a consensus target price of $20.00, indicating a potential upside of 239.56%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CNS Pharmaceuticals is more favorable than CASI Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate CASI or TRAW?

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 84.50%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Traws Pharma is more favorable than CASI Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Do analysts rate CASI or OBSV?

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than CASI Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

CASI Pharmaceuticals (CASI) Competitors

$0.21 0.00 (0.00%)

As of 09/2/2026

Compare

CASI vs. PBM, CNSP, TRAW, OBSV, and ACXP

Should you buy CASI Pharmaceuticals stock or one of its competitors? CASI Pharmaceuticals's main competitors and comparable companies include Psyence Biomedical (PBM), CNS Pharmaceuticals (CNSP), Traws Pharma (TRAW), ObsEva (OBSV), and Acurx Pharmaceuticals (ACXP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CASI Pharmaceuticals compare to Psyence Biomedical?

Psyence Biomedical (NASDAQ:PBM) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Psyence Biomedical has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Psyence Biomedical has higher earnings, but lower revenue than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.17
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

In the previous week, Psyence Biomedical's average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Psyence Biomedical	Neutral
CASI Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Psyence Biomedical has a beta of 1.72, indicating that its stock price is 72% more volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Summary

Psyence Biomedical beats CASI Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to CNS Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CNS Pharmaceuticals has lower revenue, but higher earnings than CASI Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A

CNS Pharmaceuticals has a consensus target price of $20.00, indicating a potential upside of 239.56%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CNS Pharmaceuticals is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CASI Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, suggesting that its stock price is 206% more volatile than the broader market.

In the previous week, CASI Pharmaceuticals' average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
CNS Pharmaceuticals	Neutral

CNS Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
CNS Pharmaceuticals	N/A	-204.25%	-141.87%

Summary

CASI Pharmaceuticals beats CNS Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Traws Pharma?

CASI Pharmaceuticals (NASDAQ:CASI) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 7.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CASI Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

In the previous week, CASI Pharmaceuticals' average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Traws Pharma	Neutral

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 84.50%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Traws Pharma is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Traws Pharma has lower revenue, but higher earnings than CASI Pharmaceuticals. Traws Pharma is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Traws Pharma	$2.79M	2.99	$9.17M	-$1.74	N/A

Traws Pharma has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Traws Pharma	N/A	-23,868.92%	-165.52%

Summary

Traws Pharma beats CASI Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to ObsEva?

CASI Pharmaceuticals (NASDAQ:CASI) and ObsEva (NASDAQ:OBSV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

ObsEva has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
ObsEva	N/A	-416.36%	-92.01%

CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

CASI Pharmaceuticals has higher revenue and earnings than ObsEva. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, CASI Pharmaceuticals' average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
ObsEva	Neutral

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

CASI Pharmaceuticals beats ObsEva on 7 of the 12 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Acurx Pharmaceuticals?

Acurx Pharmaceuticals (NASDAQ:ACXP) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Acurx Pharmaceuticals has higher earnings, but lower revenue than CASI Pharmaceuticals. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$2.69	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Acurx Pharmaceuticals presently has a consensus target price of $31.00, suggesting a potential upside of 2,114.29%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Acurx Pharmaceuticals is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Acurx Pharmaceuticals	Neutral
CASI Pharmaceuticals	Neutral

Acurx Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-124.73%	-87.48%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

Acurx Pharmaceuticals has a beta of -2.02, meaning that its stock price is 302% less volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Summary

Acurx Pharmaceuticals beats CASI Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get CASI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CASI vs. The Competition

Export

Metric	CASI Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.55M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.07	787.27	273.29	25.25
Price / Sales	0.10	755.95	621.79	97.64
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	1.73	12.31	13.08	6.14
Net Income	-$39.26M	$2.82B	$3.47B	$349.01M
7 Day Performance	N/A	2.59%	0.52%	-0.31%
1 Month Performance	N/A	6.95%	5.63%	0.64%
1 Year Performance	-90.90%	9.44%	25.31%	14.83%

CASI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CASI CASI Pharmaceuticals	N/A	$0.21 flat	N/A	N/A	$2.55M	$26.85M	N/A	180
PBM Psyence Biomedical	1.1232 of 5 stars	$4.27 +1.2%	N/A	-73.3%	$9.68M	N/A	0.17	N/A	Positive News
CNSP CNS Pharmaceuticals	1.7887 of 5 stars	$5.80 -2.4%	$20.00 +244.8%	-3.8%	$8.68M	N/A	N/A	5	Positive News
TRAW Traws Pharma	1.7434 of 5 stars	$0.58 +3.4%	$1.00 +72.8%	-66.3%	$8.61M	$2.79M	N/A	17
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CASI) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CASI Pharmaceuticals (CASI) Competitors

CASI vs. PBM, CNSP, TRAW, OBSV, and ACXP

How does CASI Pharmaceuticals compare to Psyence Biomedical?

Summary

How does CASI Pharmaceuticals compare to CNS Pharmaceuticals?

Summary

How does CASI Pharmaceuticals compare to Traws Pharma?

Summary

How does CASI Pharmaceuticals compare to ObsEva?

Summary

How does CASI Pharmaceuticals compare to Acurx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CASI Pharmaceuticals (CASI) Competitors

CASI vs. PBM, CNSP, TRAW, OBSV, and ACXP

How does CASI Pharmaceuticals compare to Psyence Biomedical?

Is PBM or CASI more profitable?

Do institutionals and insiders hold more shares of PBM or CASI?

Which has higher valuation and earnings, PBM or CASI?

Does the media refer more to PBM or CASI?

Do analysts prefer PBM or CASI?

Which has more risk and volatility, PBM or CASI?

Summary

How does CASI Pharmaceuticals compare to CNS Pharmaceuticals?

Do insiders & institutionals have more ownership in CASI or CNSP?

Which has better earnings and valuation, CASI or CNSP?

Do analysts recommend CASI or CNSP?

Which has more volatility & risk, CASI or CNSP?

Does the media prefer CASI or CNSP?

Is CASI or CNSP more profitable?

Summary

How does CASI Pharmaceuticals compare to Traws Pharma?

Do insiders & institutionals believe in CASI or TRAW?

Which has more volatility and risk, CASI or TRAW?

Does the media refer more to CASI or TRAW?

Do analysts rate CASI or TRAW?

Which has better earnings & valuation, CASI or TRAW?

Is CASI or TRAW more profitable?

Summary

How does CASI Pharmaceuticals compare to ObsEva?

Is CASI or OBSV more profitable?

Which has more risk & volatility, CASI or OBSV?

Which has higher valuation & earnings, CASI or OBSV?

Do analysts rate CASI or OBSV?

Does the media refer more to CASI or OBSV?

Do insiders and institutionals believe in CASI or OBSV?

Summary

How does CASI Pharmaceuticals compare to Acurx Pharmaceuticals?

Which has higher valuation and earnings, ACXP or CASI?

Do institutionals and insiders hold more shares of ACXP or CASI?

Do analysts recommend ACXP or CASI?

Does the media favor ACXP or CASI?

Is ACXP or CASI more profitable?

Which has more risk & volatility, ACXP or CASI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools